Abstracts with prescribed drug therapy, such as antimuscarinic agents. We evaluated cost-effectiveness outcomes associated with tolterodine extended release (TER), oxybutynin immediate release (OIR), and no active drug treatment in Germany and the UK (UK). METHODS: A decision-analytic model was developed for the analysis. The primary endpoint was cost-effectiveness per patient achieving persistent control (continuing therapy 6 months after initial prescription). A large case-controlled study (N = 10,041 per arm) was used to estimate persistence. Resource uses included in the model were the cost of drugs, regular physician visits, incontinence pads, and the cost of urinary tract and skin infections. These were for controlled and uncontrolled OAB. Costs were estimated from the perspective of the health care systems of Germany and the UK. Sensitivity analyses included variation of the time horizon of the analysis, unit costs, and outcomes achieved. Cost-effectiveness figures were converted to EUR2004 at market rates. RESULTS: The expected number of patients achieving persistent control at 6 months was 44% with TER and 20% with OIR. The expected cost-effectiveness per patient during 6 months in Germany was 420.89€ with TER, 224.54€ with OIR, and 51.13€ with no treatment; in the UK, respective costs were 439.20€, 292.60€, and 23.30€. The incremental cost-effectiveness per patient achieving persistent control for TER compared with no treatment was 951.70€ in the UK and 846.13€ in Germany, and compared with OIR, it was 608.28€ in the UK and 814.71€ in Germany. The model was most sensitive to changes in the time horizon considered and dose of drugs required. CONCLUSION: More than twice as many patients achieved persistent control with TER than with OIR. This persistence resulted in superior cost-effectiveness for TER compared to OIR in both the UK and Germany.
with prescribed drug therapy, such as antimuscarinic agents. We evaluated cost-effectiveness outcomes associated with tolterodine extended release (TER), oxybutynin immediate release (OIR), and no active drug treatment in Germany and the UK (UK). METHODS: A decision-analytic model was developed for the analysis. The primary endpoint was cost-effectiveness per patient achieving persistent control (continuing therapy 6 months after initial prescription). A large case-controlled study (N = 10,041 per arm) was used to estimate persistence. Resource uses included in the model were the cost of drugs, regular physician visits, incontinence pads, and the cost of urinary tract and skin infections. These were for controlled and uncontrolled OAB. Costs were estimated from the perspective of the health care systems of Germany and the UK. Sensitivity analyses included variation of the time horizon of the analysis, unit costs, and outcomes achieved. Cost-effectiveness figures were converted to EUR2004 at market rates. RESULTS: The expected number of patients achieving persistent control at 6 months was 44% with TER and 20% with OIR. The expected cost-effectiveness per patient during 6 months in Germany was 420.89€ with TER, 224.54€ with OIR, and 51.13€ with no treatment; in the UK, respective costs were 439.20€, 292.60€, and 23.30€. The incremental cost-effectiveness per patient achieving persistent control for TER compared with no treatment was 951.70€ in the UK and 846.13€ in Germany, and compared with OIR, it was 608.28€ in the UK and 814.71€ in Germany. The model was most sensitive to changes in the time horizon considered and dose of drugs required. CONCLUSION: More than twice as many patients achieved persistent control with TER than with OIR. This persistence resulted in superior cost-effectiveness for TER compared to OIR in both the UK and Germany. Overactive bladder (OAB) is a common, chronic and distressing medical condition that affects individuals of all ages, and is associated with an increased risk of comorbidities. Tolterodine is an antimuscarinic drug indicated for the treatment of OAB, and is available as both an immediate-release (IR), twice-daily, tablet formulation of tolterodine and extendedrelease (ER), once-daily, capsule formulation. The aim of this analysis is to carry out an economic evaluation of IR versus ER tolterodine in the management of OAB in Spain. METHODS: A cost-effectiveness analysis was performed by building a decision analytic model. Efficacy, tolerability and healthcare resource utilization data were obtained from a double-blind, multicenter, randomized trial showing that ER formulation was more effective and better tolerated than the IR formulation 1. Only direct medical costs-drug acquisition, physician visits, diagnostic evaluations, incontinence pads and treatment of skin complications and urinary tract infection-were taken into account. Drug costs were obtained from official sources, and the rest of data were taken from a national health care cost database. The perspective selected for this analysis was primary care assistance and the time horizon was 12 weeks, the treatment period in the referenced clinical trial. RESULTS: The percentage of patients treated with ER tolterodine had a greater control on OAB symptoms (71% vs 60%, p < 0.05) and a lower cost/effectiveness ratio (375 vs 414€ per patient with successful outcome) than patients treated with IR tolterodine. CONCLUSIONS: This model demonstrates that ER tolterodine is a more efficient therapeutic option than IR tolterodine despite of the difference in acquisition costs between the two formulations. Therefore, ER could be considered as the tolterodine formulation to be selected routinely in the management of OAB in Spain. Van Kerrebroeck et al. Urology 57: 414-421, 2001 .
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PUK3 ECONOMIC ASSESSMENT OF URO-VAXOM® IN FEMALE PATIENTS WITH RECURRENT URINARY TRACT INFECTION IN GERMANY
Brüggenjürgen B 1 , Cozma G 2 1 Alpha Care GmbH, Celle, Germany; 2 OM PHARMA, Meyrin, Switzerland OBJECTIVE: Urinary tract infections (UTIs) often lead to recurrent episodes of UTI, which are generally treated with antibiotics but the latter may induce bacterial resistance. URO-VAXOM® in addition to antibiotics reduces the incidence and severity of UTIs and improves treatment success. The objective of this decision analysis is to assess the economic impact of URO-VAXOM® taken in addition to standard medication. METHODS: A Markov model was developed for the analysis. As the health outcome variables both symptom-free quarters and disutilities due to UTIs were chosen. The model simulates the course of recurrent UTI-patients over 4 consecutive quarters. A recent randomised, multinational double-blind clinical trial conducted in 52 centres was used to calculate the treatment effect and the quarterly transition rates. Resource use included were the cost for drugs, general practitioner and specialist visit costs. Costs were estimated from the societal perspective within the framework of the German health care system. Indirect costs for absence from work were based on days off work reported in the clinical trial. Sensitivity analyses included variation of the unit costs and outcomes achieved. RESULTS: The Markov analysis resulted in 2.82 total symptom-free quarters for the placebo treatment group and 3.33 for the URO-VAXOM® treatment group. The cumulated effect over 4 quarters for the qualityadjusted life-years was 0.995 for the placebo treatment group and 0.999 for the URO-VAXOM® treatment group. The incremental cost effectiveness ratio (ICER) was 182€ for each additional symptom-free quarter generated and 23,500€ for each additional quality-adjusted life-year in Germany. The ICER was robust to variation of assumptions. CONCLUSION: Despite the decline of antibiotic's costs this economic analysis of the randomised, double-blind clinical trial showed that adding URO-VAXOM® to the standard treatment regimen has a favourable cost-benefit ratio, far below values internationally considered to be cost-effective. 2 Azienda Ospedaliera "Ospedale S. Carlo Borromeo", Milan, Italy OBJECTIVE: Reducing protein intake of patients with chronic renal disease (CRD) significantly reduces the number of patients entering end-stage renal disease (ESRD). We conducted an economic evaluation of dietary protein restriction on the progression of CRD. METHODS: We conducted a Cost-Benefit Analysis in the perspective of the Italian National Health Service (NHS) based on data from Modification in Diet in Renal Disease (MDRD) Study. In the MDRD, patients with a glomerular filtration rates (GFR) of 25-55 ml/min/1.73 m2 were randomly assigned to usual protein (1.3 g/Kg/die) or low protein (0.58 g/Kg/die) diet groups. It is expected that a patient would receive a protein-restricted diet when his/her GFR falls under 25 ml/min/1.73 m2 and to start dialysis when his/her GFR is 5 ml/min/1.73 m2. We quantified cost of diet with aprotein product (2000 Kcal/die, 40 gr/die of protein) and the assistance of a nutritionist (once every two months) and cost of dialysis using NHS tariffs. Data were applied to a 7 years time horizon. We conducted a one-way sensitivity analysis varying costs and benefits by ± 10% and applied a 3% rate of discount. RESULTS: Applying the mean decline of GFR obtained by the MDRD study we estimated patients receiving a low protein intake to start dialysis in 7 years. Patients with a usual protein diet would start dialysis in 5 years. We estimated a cost of 6882€ for 7 years low protein diet with aprotein products. This treatment would delay by 2 years dialysis initiation with an estimated saving to the NHS of 43,268€. We obtained a benefit of 36,386€ per patient. These results were robust in one-way sensitivity analyses. CONCLU-SION: Using MDRD Study data, a low protein controlled diet, in nephropatic patients, could delay the degeneration of nephropathy extending the renal survival. This involves significative economic benefits. Novartis Pharma, Vilvoorde, Brussels, Belgium; 2 Cliniques UCL Saint-Luc, Brussels, Belgium OBJECTIVE: The objective of this project was to analyse the 1-year direct medical costs of kidney transplantation performed in Belgium. METHODS: Data from the last 150 patients who received a kidney transplantation at UCL Cliniques Universitaires St Luc (Belgium) and for which a follow-up of 1-year was available were analysed. All patients were adults at the age of the transplantation and treated with cyclosporine. Patients files were retrospectively analysed. Key parameters, such as: primary hospitalisation for transplantation; immunosuppressive drug use; patient survival; graft survival; acute rejection; CMV infection; other adverse events and serious complications; treatment of adverse events; treatment of complications; repeat hospitalization; and follow-up hospital consultations were recorded. Total length of stay in the hospital was also recorded. For each patient, information up to 1-year post renal transplantation (or until death if death occurred within 1-year of transplantation) was collected. Costing information was obtained from anonymous hospital bills which provided amounts paid by the health care payer and patient. Three perspectives were considered in this study, i.e. the health care payer (INAMI/RIZIV), the patient, and the societal perspectives. RESULTS: For the whole population (n = 150), the mean direct medical costs from the societal perspective, health care payer's perspective, and patient's perspective amounted to 40,574€, 38,566€ (of which 28,844€ for hospitalisation only), and 2,008€, respectively. During this one year period, patients were hospitalised for 29 days on average. CONCLUSIONS: One year direct medical costs of kidney transplantation are substantial. In Belgium, most of the direct medical costs are borne by the health care payer, and the main cost driver are hospital costs. 4 University Cologne, Cologne, Germany OBJECTIVE: This analysis characterizes patients in need of high EPO doses at still low Hb levels of below 10 g/dl (poor EPO response). Cost-effectiveness of TR in such cohort is assessed. METHODS: A database (>9000 pat.) was stratified by EPO dosage and Hb level and analyzed according to several medical outcome parameters. A cohort of pat with poor EPO response was compared to patients with an EPO dosis of 2,500-10,600 (mean ± 1 SD) and a mean Hb level of 11.5 g/dl. Costs and consequences of EPO therapy and TR were analyzed for the cohort of pat with poor EPO response. RESULTS: Patients (n = 233) with poor EPO response (18,730 U/week) showed a mean Hb level of 9.0 g/dl and a higher prevalence of cerebrovascular, liver, and valvular heart disease and fewer days of hospital free survival time of 223 days compared to 273 days in the comparative arm. The yearly costs of EPO therapy (15,660€) outweigh the costs of transfusion therapy (5,250€) assuming 50 blood units per year. CONCLUSION: Given the relatively sick population with poor EPO response, the risks associated with TR such as infections and iron overload is outbalanced. Since mortality (historical group) and QoL (SF-36) data are available for these groups, the cost-effectiveness (cost per QALY) will be calculated.
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